But rising Chinese import tariffs due to the trade war with the U.S. and longer-term concerns about costs or access are ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pharmaceutical research and development firms in China are increasingly interested in procuring critical supplies known as ...

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

If you have decades to go before you retire, you want to make sure you own companies that know how to survive and thrive.

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

Merck KGaA is in the investment-grade market Tuesday, a day after holding investor calls, to help fund its $3.9 billion ...

The pharmaceutical giant's journey with Celonis has evolved from operational efficiency to enabling enterprise AI ...